MA37506A1 - Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21 - Google Patents

Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21

Info

Publication number
MA37506A1
MA37506A1 MA37506A MA37506A MA37506A1 MA 37506 A1 MA37506 A1 MA 37506A1 MA 37506 A MA37506 A MA 37506A MA 37506 A MA37506 A MA 37506A MA 37506 A1 MA37506 A1 MA 37506A1
Authority
MA
Morocco
Prior art keywords
growth factor
fibroblast growth
therapeutic uses
factor proteins
proteins
Prior art date
Application number
MA37506A
Other languages
English (en)
Other versions
MA37506B1 (fr
Inventor
Yanfei Linda Ma
Rovira Armando Rafael Irizarry
Vincent Louis Reynolds
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48483225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37506(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA37506A1 publication Critical patent/MA37506A1/fr
Publication of MA37506B1 publication Critical patent/MA37506B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21 (fgf21) humain.
MA37506A 2012-05-15 2013-05-09 Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21 MA37506B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261646974P 2012-05-15 2012-05-15
US201361786939P 2013-03-15 2013-03-15
PCT/US2013/040275 WO2013173158A1 (fr) 2012-05-15 2013-05-09 Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21

Publications (2)

Publication Number Publication Date
MA37506A1 true MA37506A1 (fr) 2016-01-29
MA37506B1 MA37506B1 (fr) 2017-03-31

Family

ID=48483225

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37506A MA37506B1 (fr) 2012-05-15 2013-05-09 Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21

Country Status (21)

Country Link
US (1) US20150141335A1 (fr)
EP (1) EP2852398A1 (fr)
JP (1) JP2015522539A (fr)
KR (1) KR20150002801A (fr)
CN (1) CN104302311A (fr)
AU (1) AU2013263188A1 (fr)
BR (1) BR112014028413A2 (fr)
CA (1) CA2869320A1 (fr)
CL (1) CL2014002846A1 (fr)
CO (1) CO7131381A2 (fr)
EA (1) EA201491856A1 (fr)
HK (1) HK1202800A1 (fr)
IL (1) IL235482A0 (fr)
MA (1) MA37506B1 (fr)
MX (1) MX2014013913A (fr)
PE (1) PE20142432A1 (fr)
PH (1) PH12014502537A1 (fr)
SG (1) SG11201407655TA (fr)
TN (1) TN2014000409A1 (fr)
WO (1) WO2013173158A1 (fr)
ZA (1) ZA201407532B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102077721B1 (ko) 2011-07-01 2020-02-14 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
WO2014085365A2 (fr) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions et méthodes de traitement de troubles et maladies métaboliques
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN108888757A (zh) 2012-12-27 2018-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法
WO2015065897A1 (fr) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Modèles de cancer et procédés associés
RU2701434C2 (ru) 2014-01-24 2019-09-26 Нгм Биофармасьютикалс, Инк. Связывающие белки и способы их применения
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (fr) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
JP6308699B2 (ja) * 2014-09-08 2018-04-11 国立大学法人大阪大学 脱髄疾患の予防又は治療剤
EP3209681A4 (fr) 2014-10-23 2018-10-31 NGM Biopharmaceuticals, Inc. Compositions pharmaceutiques comprenant des variants de peptide et leurs procédés d'utilisation
WO2016073855A1 (fr) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Procédés de traitement de troubles liés à l'acide biliaire et prédiction de la sensibilité clinique au traitement de troubles liés aux acides biliaires
WO2017019957A2 (fr) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Protéines de liaison et leurs procédés d'utilisation
US10744185B2 (en) 2015-11-09 2020-08-18 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of pruritus
WO2018039557A1 (fr) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19
CN108324928B (zh) * 2018-03-05 2020-09-08 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用
CN115322794A (zh) 2020-01-11 2022-11-11 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140012199A (ko) * 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos

Also Published As

Publication number Publication date
PE20142432A1 (es) 2015-01-22
TN2014000409A1 (en) 2015-12-21
JP2015522539A (ja) 2015-08-06
CA2869320A1 (fr) 2013-11-21
HK1202800A1 (en) 2015-10-09
BR112014028413A2 (pt) 2017-11-07
CN104302311A (zh) 2015-01-21
US20150141335A1 (en) 2015-05-21
MA37506B1 (fr) 2017-03-31
WO2013173158A1 (fr) 2013-11-21
ZA201407532B (en) 2016-05-25
CL2014002846A1 (es) 2015-01-30
PH12014502537A1 (en) 2015-01-21
IL235482A0 (en) 2014-12-31
SG11201407655TA (en) 2014-12-30
CO7131381A2 (es) 2014-12-01
KR20150002801A (ko) 2015-01-07
AU2013263188A1 (en) 2014-10-16
MX2014013913A (es) 2015-02-17
EP2852398A1 (fr) 2015-04-01
EA201491856A1 (ru) 2015-03-31

Similar Documents

Publication Publication Date Title
MA37506A1 (fr) Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
TR201910959T4 (tr) Elektromanyetik radyasyonun insan irisine uygulanması.
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
EA202090516A3 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
PE20150201A1 (es) Proteinas del factor 21 de crecimiento del fibroblasto
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
PH12014501702A1 (en) Imidazopyrrolidinone compounds
EA201590962A1 (ru) Новые соединения
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
ECSP12012348A (es) Agentes inductores de apoptosis contra el cáncer y de enfermedades inmunes y autoinmunes
NZ706189A (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
IN2014DN11201A (fr)
MA34521B1 (fr) Polypeptides de relaxine modifiés et leurs utilisations
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
MD3355919T2 (ro) Terapie combinată cu utilizarea inhibitorilor factorului de creștere și diferențiere uman 15 (GDF-15) și a blocanților punctelor de control imunitar
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
FR3003173B1 (fr) Substituts osseux greffes par des peptides mimetiques de la proteine humaine bmp-2.
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы